Expression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression

References

• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76(5):639–657.
   PubMed Web of Science ®Google Scholar
• Antonova O, Toncheva D, Grigorov E. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes. J BUON. 2015;20(6):1397–1406.
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531.
   PubMed Web of Science ®Google Scholar
• Di Pierro GB, Gulia C, Cristini C, et al. Bladder cancer: a simple model becomes complex. Curr Genomics. 2012;13(5):395–415.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Witjes JA, Compérat E, Cowan NC, et al. European Association of Urology Guidelines on Bladder Cancer Muscle-invasive and Metastatic, E.A.o. Urology, editor. 2012. Available from: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
   Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238.
   PubMed Web of Science ®Google Scholar
• Han E-S, Wu Y, McCarter R, et al. Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. J Gerontol A Biol Sci Med Sci. 2004;59(4):306–315.
   PubMed Web of Science ®Google Scholar
• Fang W, Li X, Jiang Q, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;6:32.
   PubMed Web of Science ®Google Scholar
• Wattel S, Mircescu H, Venet D, et al. Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene. 2005;24(46):6902–6916.
   PubMed Web of Science ®Google Scholar
• Saner-Amigh K, Mayhew BA, Mantero F, et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J Clin Endocrinol Metab. 2006;91(3):1136–1142.
   PubMed Web of Science ®Google Scholar
• Durkin AJ, Bloomston M, Yeatman TJ, et al. Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg. 2004;199(5):724–731.
   PubMed Web of Science ®Google Scholar
• Birkenkamp-Demtroder K, Christensen LL, Olesen SH, et al. Gene expression in colorectal cancer. Cancer Res. 2002;62(15):4352–4363.
   PubMed Web of Science ®Google Scholar
• Yang H, Gu J, Lin X, et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res. 2008;14(7):2236–2244.
   PubMed Web of Science ®Google Scholar
• Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23(24):5746–5756.
   PubMed Web of Science ®Google Scholar
• Verbeke H, Hannelien V, Geboes K, et al. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 2012;1825(1):117–129.
   PubMed Web of Science ®Google Scholar
• Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol. 2009;66(1):44–53.
   PubMedGoogle Scholar
• Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol. 2001;69(4):513–521.
   PubMed Web of Science ®Google Scholar
• Barclay J, Creswell J, Leon J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol. 2018;71(4):393–399.
   PubMed Web of Science ®Google Scholar
• Li B, Xie D, Zhang H. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer. Cancer Chemother Pharmacol. 2019;84(1):187–194.
   PubMed Web of Science ®Google Scholar
• Partanen L, Staaf J, Tanner M, et al. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes Cancer. 2012;51(9):832–840.
   PubMed Web of Science ®Google Scholar
• Liu X, Yao D, Liu C, et al. Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. Tumour Biol. 2016;37(6):8367–8374.
   PubMedGoogle Scholar
• Sjodahl G, et al. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol. 2019;247(5):563–573.
   PubMed Web of Science ®Google Scholar
• Feng S, Cao Z, Wang X. Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta. 2013;1836(2):197–210.
   PubMed Web of Science ®Google Scholar
• Tsay JJ, Tchou-Wong K-M, Greenberg AK, et al. Aryl hydrocarbon receptor and lung cancer. Anticancer Res. 2013;33(4):1247–1256.
   PubMed Web of Science ®Google Scholar
• Ishida M, Mikami S, Kikuchi E, et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis. 2010;31(2):287–295.
   PubMed Web of Science ®Google Scholar
• Gundert-Remy U, Bernauer U, Blömeke B, et al. Extrahepatic metabolism at the body's internal-external interfaces. Drug Metab Rev. 2014;46(3):291–324.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C, et al. PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway. Mol Med Rep. 2016;13(1):333–338.
   PubMed Web of Science ®Google Scholar
• Salman T, el-Ahmady O, el-Shafee M, et al. Cathepsin-D and TNF-alpha in bladder cancer. Dis Markers. 1996;12(4):253–259.
   PubMed Web of Science ®Google Scholar
• Gorodkiewicz E, Guszcz T, Roszkowska-Jakimiec W, et al. Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging. Oncol Lett. 2014;8(3):1323–1327.
   PubMed Web of Science ®Google Scholar
• Niegisch G, Knievel J, Koch A, et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 2013;31(8):1770–1779.
   PubMed Web of Science ®Google Scholar
• Poyet C, Jentsch B, Hermanns T, et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol. 2014;14(1):10.
   PubMedGoogle Scholar
• Yang Y, Liu K, Yang L, et al. Bladder cancer cell viability inhibition and apoptosis induction by baicalein through targeting the expression of anti-apoptotic genes. Saudi J Biol Sci. 2018;25(7):1478–1482.
   PubMed Web of Science ®Google Scholar
• Chen D, Chen J, Guo Y, et al. Cinobufacini promotes apoptosis of bladder cancer cells by influencing the expression of autophagy-related genes. Oncol Lett. 2018;15(5):7104–7110.
   PubMed Web of Science ®Google Scholar
• Jung JH, You S, Oh JW, et al. Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Lett. 2018;437:1–12.
   PubMed Web of Science ®Google Scholar
• Rubio C, Martínez-Fernández M, Segovia C, et al. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status. Clin Cancer Res. 2019;25(1):390–402.
   PubMed Web of Science ®Google Scholar
• Verma H, Sharma T, Gupta S, et al. CYP1A1 expression and organochlorine pesticides level in the etiology of bladder cancer in North Indian population. Hum Exp Toxicol. 2018;37(8):817–826.
   PubMed Web of Science ®Google Scholar
• Sato K, Sasaki R, Ogura Y, et al. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med. 1998;185(3):173–184.
   PubMed Web of Science ®Google Scholar
• Takamura T, Horinaka M, Yasuda S, et al. FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells. Oncol Rep. 2018;39(2):627–632.
   PubMed Web of Science ®Google Scholar
• Ouerhani S, Elgaaied AB. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Cancer Biomark. 2011;10(6):259–266.
   PubMed Web of Science ®Google Scholar
• Broude EV, Győrffy B, Chumanevich AA, et al. Expression of CDK8 and CDK8-interacting genes as potential biomarkers in breast cancer. Curr Cancer Drug Targets. 2015;15(8):739–749.
   PubMed Web of Science ®Google Scholar
• Bellan C, De Falco G, Lazzi S, et al. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol. 2004;203(4):946–952.
   PubMed Web of Science ®Google Scholar
• De Falco G, Giordano A. CDK9: from basal transcription to cancer and AIDS. Cancer Biol Ther. 2002;1(4):342–347.
   PubMed Web of Science ®Google Scholar
• Mohapatra S, Chu B, Zhao X, et al. Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. Int J Biochem Cell Biol. 2009;41(3):595–602.
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Walter RFH, Werner R, et al. Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carcinomas and is crucial for carcinoid tumourgenesis. J Cancer. 2014;5(6):465–471.
   PubMed Web of Science ®Google Scholar
• Ji L, Zheng Z, Shi L, et al. Andrographolide decreased VEGFD expression in hepatoma cancer cells by inducing ubiquitin/proteasome-mediated cFos protein degradation. Biochim Biophys Acta. 2015;1850(4):750–758.
   PubMed Web of Science ®Google Scholar
• Gao L, Cueto MA, Asselbergs F, et al. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002;277(28):25748–25755.
   PubMed Web of Science ®Google Scholar
• Deubzer HE, Schier MC, Oehme I, et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer. 2013;132(9):2200–2208.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang X, Li X, et al. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. Oncol Rep. 2018;39(2):818–826.
   PubMed Web of Science ®Google Scholar
• Ong HS, Gokavarapu S, Tian Z, et al. PDGFRA mRNA is overexpressed in oral cancer patients as compared to normal subjects with a significant trend of overexpression among tobacco users. J Oral Pathol Med. 2017;46(8):591–597.
   PubMed Web of Science ®Google Scholar